vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and JBT Marel Corp (JBTM). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $1.0B, roughly 1.1× JBT Marel Corp). JBT Marel Corp runs the higher net margin — 5.3% vs -24.1%, a 29.4% gap on every dollar of revenue. On growth, JBT Marel Corp posted the faster year-over-year revenue change (115.6% vs 12.2%). JBT Marel Corp produced more free cash flow last quarter ($83.5M vs $46.0M). Over the past eight quarters, JBT Marel Corp's revenue compounded faster (60.3% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
JBT Marel Corporation, formerly known as JBT Corporation, or John Bean Technologies Corporation, is a food processing machinery and automated vehicle company. The company was incorporated in 2008 when FMC Technologies divested its non-energy businesses. The company is based in Chicago, Illinois and traces its history back to a company founded in 1884 by John Bean, an orchardist in Los Gatos, California.
ELAN vs JBTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.0B |
| Net Profit | $-276.0M | $53.1M |
| Gross Margin | 51.5% | 34.5% |
| Operating Margin | -22.6% | 7.2% |
| Net Margin | -24.1% | 5.3% |
| Revenue YoY | 12.2% | 115.6% |
| Net Profit YoY | -3350.0% | 858.6% |
| EPS (diluted) | $-0.55 | $1.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.0B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.2B | $934.8M | ||
| Q1 25 | $1.2B | $854.1M | ||
| Q4 24 | $1.0B | $467.6M | ||
| Q3 24 | $1.0B | $453.8M | ||
| Q2 24 | $1.2B | $402.3M | ||
| Q1 24 | $1.2B | $392.3M |
| Q4 25 | $-276.0M | $53.1M | ||
| Q3 25 | $-34.0M | $66.0M | ||
| Q2 25 | $11.0M | $3.4M | ||
| Q1 25 | $67.0M | $-173.0M | ||
| Q4 24 | $-8.0M | $-7.0M | ||
| Q3 24 | $364.0M | $38.9M | ||
| Q2 24 | $-50.0M | $30.7M | ||
| Q1 24 | $32.0M | $22.8M |
| Q4 25 | 51.5% | 34.5% | ||
| Q3 25 | 53.4% | 35.9% | ||
| Q2 25 | 57.5% | 35.8% | ||
| Q1 25 | 57.3% | 34.2% | ||
| Q4 24 | 50.9% | 38.4% | ||
| Q3 24 | 52.2% | 36.1% | ||
| Q2 24 | 58.2% | 35.6% | ||
| Q1 24 | 57.3% | 35.8% |
| Q4 25 | -22.6% | 7.2% | ||
| Q3 25 | -4.4% | 10.2% | ||
| Q2 25 | 2.0% | 5.2% | ||
| Q1 25 | 5.0% | -3.9% | ||
| Q4 24 | -5.0% | 3.4% | ||
| Q3 24 | 54.3% | 10.3% | ||
| Q2 24 | -2.7% | 6.7% | ||
| Q1 24 | 1.0% | 7.4% |
| Q4 25 | -24.1% | 5.3% | ||
| Q3 25 | -3.0% | 6.6% | ||
| Q2 25 | 0.9% | 0.4% | ||
| Q1 25 | 5.6% | -20.3% | ||
| Q4 24 | -0.8% | -1.5% | ||
| Q3 24 | 35.3% | 8.6% | ||
| Q2 24 | -4.2% | 7.6% | ||
| Q1 24 | 2.7% | 5.8% |
| Q4 25 | $-0.55 | $1.04 | ||
| Q3 25 | $-0.07 | $1.26 | ||
| Q2 25 | $0.02 | $0.07 | ||
| Q1 25 | $0.13 | $-3.35 | ||
| Q4 24 | $-0.01 | $-0.22 | ||
| Q3 24 | $0.73 | $1.21 | ||
| Q2 24 | $-0.10 | $0.95 | ||
| Q1 24 | $0.06 | $0.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $167.9M |
| Total DebtLower is stronger | $3.9B | $1.5B |
| Stockholders' EquityBook value | $6.5B | $4.5B |
| Total Assets | $13.4B | $8.2B |
| Debt / EquityLower = less leverage | 0.60× | 0.33× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $167.9M | ||
| Q3 25 | $505.0M | — | ||
| Q2 25 | $539.0M | — | ||
| Q1 25 | $487.0M | — | ||
| Q4 24 | $468.0M | $1.2B | ||
| Q3 24 | $490.0M | — | ||
| Q2 24 | $416.0M | — | ||
| Q1 24 | $345.0M | — |
| Q4 25 | $3.9B | $1.5B | ||
| Q3 25 | $4.0B | $1.5B | ||
| Q2 25 | $4.1B | $1.5B | ||
| Q1 25 | $4.4B | $2.0B | ||
| Q4 24 | $4.3B | $1.3B | ||
| Q3 24 | $4.4B | $648.3M | ||
| Q2 24 | $5.7B | $647.7M | ||
| Q1 24 | $5.8B | $647.0M |
| Q4 25 | $6.5B | $4.5B | ||
| Q3 25 | $6.7B | $4.4B | ||
| Q2 25 | $6.8B | $4.4B | ||
| Q1 25 | $6.4B | $4.1B | ||
| Q4 24 | $6.1B | $1.5B | ||
| Q3 24 | $6.5B | $1.6B | ||
| Q2 24 | $5.9B | $1.5B | ||
| Q1 24 | $6.1B | $1.5B |
| Q4 25 | $13.4B | $8.2B | ||
| Q3 25 | $13.6B | $8.2B | ||
| Q2 25 | $13.7B | $8.3B | ||
| Q1 25 | $12.9B | $8.0B | ||
| Q4 24 | $12.6B | $3.4B | ||
| Q3 24 | $13.3B | $2.8B | ||
| Q2 24 | $13.8B | $2.7B | ||
| Q1 24 | $14.0B | $2.7B |
| Q4 25 | 0.60× | 0.33× | ||
| Q3 25 | 0.59× | 0.34× | ||
| Q2 25 | 0.61× | 0.35× | ||
| Q1 25 | 0.69× | 0.48× | ||
| Q4 24 | 0.70× | 0.81× | ||
| Q3 24 | 0.67× | 0.41× | ||
| Q2 24 | 0.96× | 0.43× | ||
| Q1 24 | 0.95× | 0.43× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $117.4M |
| Free Cash FlowOCF − Capex | $46.0M | $83.5M |
| FCF MarginFCF / Revenue | 4.0% | 8.3% |
| Capex IntensityCapex / Revenue | 5.4% | 3.4% |
| Cash ConversionOCF / Net Profit | — | 2.21× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $238.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $117.4M | ||
| Q3 25 | $219.0M | $87.7M | ||
| Q2 25 | $237.0M | $102.2M | ||
| Q1 25 | $-4.0M | $34.4M | ||
| Q4 24 | $177.0M | $128.7M | ||
| Q3 24 | $162.0M | $71.9M | ||
| Q2 24 | $200.0M | $21.6M | ||
| Q1 24 | $2.0M | $10.4M |
| Q4 25 | $46.0M | $83.5M | ||
| Q3 25 | $127.0M | $56.5M | ||
| Q2 25 | $180.0M | $83.7M | ||
| Q1 25 | $-69.0M | $14.4M | ||
| Q4 24 | $130.0M | $118.7M | ||
| Q3 24 | $120.0M | $65.0M | ||
| Q2 24 | $166.0M | $11.1M | ||
| Q1 24 | $-22.0M | $-100.0K |
| Q4 25 | 4.0% | 8.3% | ||
| Q3 25 | 11.2% | 5.6% | ||
| Q2 25 | 14.5% | 9.0% | ||
| Q1 25 | -5.8% | 1.7% | ||
| Q4 24 | 12.7% | 25.4% | ||
| Q3 24 | 11.7% | 14.3% | ||
| Q2 24 | 14.0% | 2.8% | ||
| Q1 24 | -1.8% | -0.0% |
| Q4 25 | 5.4% | 3.4% | ||
| Q3 25 | 8.1% | 3.1% | ||
| Q2 25 | 4.6% | 2.0% | ||
| Q1 25 | 5.4% | 2.3% | ||
| Q4 24 | 4.6% | 2.1% | ||
| Q3 24 | 4.1% | 1.5% | ||
| Q2 24 | 2.9% | 2.6% | ||
| Q1 24 | 2.0% | 2.7% |
| Q4 25 | — | 2.21× | ||
| Q3 25 | — | 1.33× | ||
| Q2 25 | 21.55× | 30.06× | ||
| Q1 25 | -0.06× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | 1.85× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | 0.06× | 0.46× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
JBTM
Segment breakdown not available.
